Fusion Pharmaceuticals Inc. (FUSN)

Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
CEO:
John Valliant
Employees:
90
270 LONGWOOD ROAD SOUTH, HAMILTON, CANADA L8P 0A6
289-799-0891

Fusion Pharmaceuticals Inc. focuses on developing radiopharmaceuticals as precision medicines. Its lead product candidate is FPI-1434 that is in Phase 1 clinical trials as a monotherapy in patients with solid tumors expressing insulin-like growth factor 1 receptor.

Data derived from most recent annual or quarterly report
Market Cap 98.821 Million Shares Outstanding43.342 Million Avg 30-day Volume 44.589 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS-0.63
Price to Revenue166.3064 Debt to Equity0.0 EBITDA-81.847 Million
Price to Book Value1.5633 Operating Margin-4190.6173 Enterprise Value129.628 Million
Current Ratio16.81 EPS Growth-1.985 Quick Ratio16.183
1 Yr BETA 0.2994 52-week High/Low 9.5 / 2.2 Profit Margin-4119.8519
Operating Cash Flow Growth-64.0386 Altman Z-Score8.3835 Free Cash Flow to Firm -67.501 Million
Earnings Report2022-08-09
View SEC Filings from FUSN instead.

View recent insider trading info

Funds Holding FUSN (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding FUSN BETA

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Events (8k)

  • 8-K: filed on 2022-06-21:
    Item 5.07: Submission of Matters to a Vote of Security Holders
  • 8-K: filed on 2022-06-09:
    Item 7.01: Regulation FD Disclosure
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-05-10:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-04-13:
    Item 8.01: Other Events
  • 8-K: filed on 2022-04-04:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
    Item 3.02: Unregistered Sales of Equity Securities
    Item 8.01: Other Events
  • 8-K: filed on 2022-03-17:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-11-09:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-08-13:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-08-10:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K/A: filed on 2021-07-23:
    Item 9.01: Financial Statements and Exhibits
  • Prospectus

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    CAGNONI PABLO J

    • Director
    17,000 2022-06-14 1

    DUNCAN BARBARA GAYLE

    • Director
    17,000 2022-06-14 1

    PRESTON HEATHER

    • Director
    17,000 2022-06-14 1

    KHUONG CHAU QUANG

    • Director
    17,000 2022-06-14 1

    GANNON STEVEN

    • Director
    17,000 2022-06-14 4

    LEE PHILINA

    • Director
    17,000 2022-06-14 1

    VALLIANT JOHN CHIEF EXECUTIVE OFFICER

    • Officer
    • Director
    318,147 2022-04-25 17

    O'LEARY JAMES J CHIEF MEDICAL OFFICER

    • Officer
    161,022 2022-02-01 1

    CROWLEY JOHN J CHIEF FINANCIAL OFFICER

    • Officer
    177,410 2022-02-01 1

    BURAK ERIC CHIEF? SCIENTIFIC OFFICER

    • Officer
    168,200 2022-02-01 1

    RAWAT MOHIT PRESIDENT AND CBO

    • Officer
    77,900 2022-02-01 3

    LEAMON CHRISTOPHER P CHIEF SCIENTIFIC OFFICER

    • Officer
    218,000 2021-11-01 2

    BERGSTROM DONALD A

    • Director
    17,000 2021-06-14 0

    ADAMS STREET PARTNERS LLC

    • 10% Owner
    No longer subject to file 2020-12-24 0

    JOHNSON & JOHNSON

    JOHNSON & JOHNSON INNOVATION - JJDC, INC.

    • 10% Owner
    No longer subject to file 2020-06-30 0

    TPG GROUP HOLDINGS (SBS) ADVISORS, INC.

    BONDERMAN DAVID

    COULTER JAMES G

    • FORMER 10% OWNERFORMER 10% OWNERFORMER 10% OWNER
    No longer subject to file 2020-06-30 0

    ORBIMED ADVISORS LLC

    ORBIMED CAPITAL GP VII LLC

    ORBIMED CAPITAL LLC

    • Director
    3,122,770 2020-06-30 0

    CHRISTENSON JOHAN

    • Director
    3,807,247 2020-06-30 0

    HEALTHCAP VII, L.P.

    HEALTHCAP VII GP S.A.

    • 10% Owner
    No longer subject to file 2020-06-30 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed
    Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

    BERGSTROM DONALD A - Director

    2022-06-22 19:03:15 -0400 2022-06-14 A 17,000 a 17,000 direct

    CAGNONI PABLO J - Director

    2022-06-22 19:05:53 -0400 2022-06-14 A 17,000 a 17,000 direct

    DUNCAN BARBARA GAYLE - Director

    2022-06-22 19:07:42 -0400 2022-06-14 A 17,000 a 17,000 direct

    GANNON STEVEN - Director

    2022-06-22 19:09:24 -0400 2022-06-14 A 17,000 a 17,000 direct

    KHUONG CHAU QUANG - Director

    2022-06-22 19:12:26 -0400 2022-06-14 A 17,000 a 17,000 direct

    LEE PHILINA - Director

    2022-06-22 19:14:58 -0400 2022-06-14 A 17,000 a 17,000 direct

    PRESTON HEATHER - Director

    2022-06-22 19:16:36 -0400 2022-06-14 A 17,000 a 17,000 direct

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    FUSION PHARMACEUTICALS INC FUSN 2022-08-05 22:15:04 UTC -23.1296 25.4496 850000
    FUSION PHARMACEUTICALS INC FUSN 2022-08-05 21:45:03 UTC -23.1296 25.4496 850000
    FUSION PHARMACEUTICALS INC FUSN 2022-08-05 21:15:03 UTC -23.1296 25.4496 850000
    FUSION PHARMACEUTICALS INC FUSN 2022-08-05 20:45:04 UTC -23.1296 25.4496 850000
    FUSION PHARMACEUTICALS INC FUSN 2022-08-05 20:15:05 UTC -23.1296 25.4496 850000
    FUSION PHARMACEUTICALS INC FUSN 2022-08-05 19:45:04 UTC -23.1296 25.4496 850000
    FUSION PHARMACEUTICALS INC FUSN 2022-08-05 19:15:05 UTC -23.1296 25.4496 850000
    FUSION PHARMACEUTICALS INC FUSN 2022-08-05 18:45:04 UTC -23.1296 25.4496 850000
    FUSION PHARMACEUTICALS INC FUSN 2022-08-05 18:15:03 UTC -23.1296 25.4496 850000
    FUSION PHARMACEUTICALS INC FUSN 2022-08-05 17:45:04 UTC -23.1296 25.4496 850000
    FUSION PHARMACEUTICALS INC FUSN 2022-08-05 17:15:04 UTC -23.1296 25.4496 850000
    FUSION PHARMACEUTICALS INC FUSN 2022-08-05 16:45:05 UTC -23.266 25.586 850000
    FUSION PHARMACEUTICALS INC FUSN 2022-08-05 16:15:05 UTC -23.266 25.586 850000
    FUSION PHARMACEUTICALS INC FUSN 2022-08-05 15:45:04 UTC -23.266 25.586 850000
    FUSION PHARMACEUTICALS INC FUSN 2022-08-05 15:15:03 UTC -23.266 25.586 850000
    FUSION PHARMACEUTICALS INC FUSN 2022-08-05 14:45:04 UTC -23.266 25.586 850000
    FUSION PHARMACEUTICALS INC FUSN 2022-08-05 14:15:04 UTC -23.266 25.586 850000
    FUSION PHARMACEUTICALS INC FUSN 2022-08-05 13:45:05 UTC -23.266 25.586 850000
    FUSION PHARMACEUTICALS INC FUSN 2022-08-05 13:15:04 UTC -23.266 25.586 850000
    FUSION PHARMACEUTICALS INC FUSN 2022-08-05 12:45:05 UTC -23.266 25.586 850000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin

    Elevate your investments